Compare ICCM & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCM | AEMD |
|---|---|---|
| Founded | 2006 | 1984 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.9M |
| IPO Year | 2013 | 2008 |
| Metric | ICCM | AEMD |
|---|---|---|
| Price | $0.72 | $5.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $22.67 | $13.25 |
| AVG Volume (30 Days) | ★ 110.0K | 42.8K |
| Earning Date | 11-18-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.11 | N/A |
| Revenue Next Year | $104.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.13 | $0.53 |
| 52 Week High | $9.54 | $25.20 |
| Indicator | ICCM | AEMD |
|---|---|---|
| Relative Strength Index (RSI) | 29.69 | 48.11 |
| Support Level | $0.65 | $4.86 |
| Resistance Level | $0.74 | $6.09 |
| Average True Range (ATR) | 0.10 | 0.39 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 18.43 | 22.33 |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.